Wedbush Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has initiated coverage on Perspective Therapeutics (AMEX:CATX) with an Outperform rating and set a price target of $25.
October 01, 2024 | 9:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has initiated coverage on Perspective Therapeutics with an Outperform rating and a price target of $25, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $25 by a reputable analyst can lead to increased investor interest and potential buying activity, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100